MarketCap
Facebook
X
Telegram
Celyad Oncology SA Income Statement 2022-2011 | CYAD
Brief overview of financial results at Celyad Oncology SA
This overview is based on financial performance over the past five years. Revenue at Celyad Oncology SA moved from 3 thousand euros in 2015 to 5 thousand euros in 2020. The five-year change reached +66.7%, while CAGR stood at 10.8%. The company expanded its sales base at a healthy rate.
The gross result shifted from 1 thousand euros to 5 thousand euros, or +400%. Gross margin moved from 33.3% to 100%. Improving gross profitability strengthens the quality of revenue growth.
Over the period, EBITDA shifted from −28.7 million euros to −17 million euros, a change of +40.9%. EBITDA underperformed the top-line trend. Comparing the endpoints gives EBITDA margins of −957966.7% and −339740%. A wider margin confirms stronger operating efficiency.
Comparing the endpoints shows a move from −29.1 million euros to −17.2 million euros. The loss narrowed, although sustainable profitability has not yet returned.
The five-year change in capitalization reached −69.5%: from 349 million euros to 106 million euros. Investors remain cautious despite better financial results.
Conclusion
The figures do not all move in the same direction. Key strengths include a larger revenue base, positive operating leverage and better sales economics. The most visible risks are a weaker market valuation and a low EBITDA margin. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Celyad Oncology SA
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
10.6 M | 41.7 M | 106 M | 105 M | 232 M | 380 M | 206 M | 349 M | - | - | - | - |
Shares |
22.6 M | 15.6 M | 13.9 M | 12.5 M | 11.1 M | 9.63 M | 9.31 M | 8.48 M | - | - | - | - |
Historical Prices |
0.47 | 2.67 | 7.63 | 8.39 | 20.9 | 39.5 | 22.1 | 41.1 | - | - | - | - |
Net Income |
-40.9 M | -26.5 M | -17.2 M | -28.6 M | -37.4 M | -56.4 M | -23.6 M | -29.1 M | -16.5 M | -12.3 M | -2.15 M | -9.13 M |
Revenue |
- | - | 5 K | 6 K | 3.12 M | 3.54 M | 10 M | 3 K | 146 K | - | 54 K | 26.9 K |
Cost of Revenue |
- | - | - | - | - | 515 K | 1.54 M | 2 K | - | - | - | - |
Gross Profit |
- | - | 5 K | 6 K | 3.12 M | 3.02 M | 8.47 M | 1 K | 31 K | -2.42 M | -6.63 M | -5.77 M |
Operating Income |
-40.9 M | -26.4 M | -17 M | -28.9 M | -38.2 M | -52.9 M | -25.6 M | - | - | - | - | - |
EBITDA |
-40.9 M | -26.4 M | -17 M | -28.9 M | -38.2 M | -52.9 M | -25.6 M | -28.7 M | -19 M | -11 M | 440 K | -6.36 M |
Operating Expenses |
- | - | 26.2 M | 29.4 M | 34.5 M | 52.9 M | 25.6 M | 29.7 M | 19.9 M | 8.66 M | -5.19 M | 3.31 M |
General and Administrative Expenses |
10.5 M | 9.91 M | 200 K | 9.1 M | 10.4 M | 9.31 M | 9.74 M | 7.23 M | 4.62 M | 2.99 M | 3.71 M | 2.84 M |
All numbers in EUR currency
Quarterly Income Statement Celyad Oncology SA
| 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
22.6 M | 22.6 M | - | 22.6 M | - | 15.6 M | - | 14.6 M | - | 13.9 M | - | 13.9 M | - | 12.5 M | - | 11.9 M | - | 11.1 M | - | - | - | 9.63 M | - | - | - | 9.31 M | - | - | - | 8.48 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-3.74 M | -40.9 M | - | -14.1 M | - | -26.5 M | - | -14.9 M | - | -17.2 M | - | -16.6 M | - | -28.6 M | - | -16 M | - | -37.4 M | - | - | - | -56.4 M | - | - | - | -23.6 M | - | - | - | -29.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
44 K | - | - | - | - | - | - | - | - | 5 K | - | 5 K | - | 6 K | - | 2.52 M | - | 3.12 M | - | - | - | 3.54 M | - | - | - | 10 M | - | - | - | 3 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
44 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 515 K | - | - | - | 1.54 M | - | - | - | 2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | 5 K | - | 5 K | - | 5 K | - | 6 K | - | 2.52 M | - | 3.12 M | - | - | - | 3.02 M | - | - | - | 8.47 M | - | - | - | 1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-3.74 M | -40.9 M | - | -14.1 M | - | -26.4 M | - | -14.9 M | - | -17 M | - | -16.6 M | - | -28.9 M | - | -16 M | - | -38.2 M | - | - | - | -52.9 M | - | - | - | -25.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-3.74 M | -40.9 M | - | -14.1 M | - | -26.4 M | - | -14.9 M | - | -17 M | - | -16.6 M | - | -28.9 M | - | -16 M | - | -38.2 M | - | - | - | -52.9 M | - | - | - | -25.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.9 M | - | - | - | 25.6 M | - | - | - | 29.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
3.66 M | 10.5 M | - | 6.24 M | - | 9.91 M | - | 4.78 M | - | 200 K | - | 4.79 M | - | 9.1 M | - | 4.51 M | - | 10.4 M | - | - | - | 9.31 M | - | - | - | 9.74 M | - | - | - | 7.23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
The income statement is one of the three key financial reports of a company Celyad Oncology SA (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Cayman-islands
